<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965948</url>
  </required_header>
  <id_info>
    <org_study_id>14012021</org_study_id>
    <secondary_id>E47F17000020009</secondary_id>
    <nct_id>NCT04965948</nct_id>
  </id_info>
  <brief_title>Effects of Camelina Sativa Oil in Free-living Older Adults</brief_title>
  <official_title>Evaluation of the Anti-inflammatory Effects of a Snack Enriched With Camelina Sativa Oil in Free-living Older Adults: a Randomized, Double-blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pavia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims at evaluating the anti-inflammatory effects of a novel food in older&#xD;
      adult volunteers. Briefly, this randomized, double-blind and placebo-controlled study is&#xD;
      performed on 91 apparently healthy older adults (age≥65 years) before and after 12 weeks'&#xD;
      consumption of a snack enriched with camelina Sativa oil. Subjects were randomized into two&#xD;
      groups (active group vs placebo group).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ninety-one volunteers (26M/65F) are enrolled according to the following inclusion criteria i)&#xD;
      free-living older adults ≥ 65 years; ii) apparently healthy subjects; iii) subjects who do&#xD;
      not take vitamin supplements/integration and/or omega 3 polyunsaturated fatty acids; iv)&#xD;
      subjects without food allergies.&#xD;
&#xD;
      All volunteers are informed about the purpose of the study and the potential risk and provide&#xD;
      their informed consent.&#xD;
&#xD;
      Subjects are randomized into two groups: active group (13M/36F) vs placebo group (13M/29F).&#xD;
&#xD;
      The main objective of this project is to test the efficacy of the 12-weeks consumption of a&#xD;
      novel food (snack enriched with camelina Sativa oil) on the inflammatory status in older&#xD;
      adults.&#xD;
&#xD;
      The primary and secondary endpoints are:&#xD;
&#xD;
      i) Investigation of changes in serum CRP levels and serum levels of pro- and&#xD;
      anti-inflammatory cytokines, in the active group (volunteers consumed enriched snack with&#xD;
      camelina Sativa oil) and placebo group, after 12 weeks of snacking (T1), compared to baseline&#xD;
      (T0) (primary endpoint).&#xD;
&#xD;
      ii) Evaluation of changes in serum lipid panel parameters after the consumption of the novel&#xD;
      food in both the active and placebo groups (secondary endpoint).&#xD;
&#xD;
      iii) Evaluation of changes in glucidic status after the consumption of the novel food in both&#xD;
      the active and placebo groups (secondary endpoint).&#xD;
&#xD;
      iv) Evaluation of changes in the levels of omega 3 polyunsaturated fatty acids in both the&#xD;
      active and placebo groups (secondary endpoint).&#xD;
&#xD;
      v) Evaluation of the nutritional status at T0 and at T1 in both the active and placebo groups&#xD;
      (secondary endpoint).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 7, 2019</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory status evaluation.</measure>
    <time_frame>Baseline (T0) and after 12 weeks of intervention (T1).</time_frame>
    <description>Investigation of changes in serum CRP levels (pg/mL) and serum levels of pro- and anti- inflammatory cytokines (TNF-α, pg/mL; TGF-beta1, pg/mL and TGF-beta2, pg/mL; IL-18 pg/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid panel parameters evaluation.</measure>
    <time_frame>Baseline (T0) and after 12 weeks of intervention (T1).</time_frame>
    <description>Evaluation of changes in serum lipid panel parameters (total cholesterol, mg/dL; triglycerides, mg/dL; HDL cholesterol, mg/dL; LDL cholesterol, mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Omega 3 polyunsaturated fatty acids evaluation.</measure>
    <time_frame>Baseline (T0) and after 12 weeks of intervention (T1).</time_frame>
    <description>Evaluation of changes in the levels of omega 3 polyunsaturated fatty acids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucidic profile evaluation -glucose levels</measure>
    <time_frame>Baseline (T0) and after 12 weeks of intervention (T1).</time_frame>
    <description>Evaluation of changes in the levels of glucose (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucidic profile evaluation - insulin levels</measure>
    <time_frame>Baseline (T0) and after 12 weeks of intervention (T1).</time_frame>
    <description>Evaluation of changes in the levels of insulin (μU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucidic profile evaluation - glycated haemoglobin levels</measure>
    <time_frame>Baseline (T0) and after 12 weeks of intervention (T1).</time_frame>
    <description>Evaluation of changes in the levels of glycated haemoglobin (mmol/mol).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucidic profile evaluation - HOMA index</measure>
    <time_frame>Baseline (T0) and after 12 weeks of intervention (T1).</time_frame>
    <description>Evaluation of changes in the HOMA index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status evaluation - hepatic function</measure>
    <time_frame>Baseline (T0) and after 12 weeks of intervention (T1).</time_frame>
    <description>Evaluation of nutritional status by assessing the serum levels of ALT (U/L), AST (U/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status evaluation - renal function</measure>
    <time_frame>Baseline (T0) and after 12 weeks of intervention (T1).</time_frame>
    <description>Evaluation of nutritional status by assessing the serum levels of creatinine (mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status evaluation.</measure>
    <time_frame>Baseline (T0) and after 12 weeks of intervention (T1).</time_frame>
    <description>Evaluation of nutritional status by assessing the serum levels of prealbumin (g/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status evaluation - micronutrients</measure>
    <time_frame>Baseline (T0) and after 12 weeks of intervention (T1).</time_frame>
    <description>Evaluation of nutritional status by assessing the calcium (mg/dL), magnesium (mg/dL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status evaluation - micronutrients</measure>
    <time_frame>Baseline (T0) and after 12 weeks of intervention (T1).</time_frame>
    <description>Evaluation of nutritional status by assessing the serum levels of iron (μg/dL) and zinc (μg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status evaluation - vitamins</measure>
    <time_frame>Baseline (T0) and after 12 weeks of intervention (T1).</time_frame>
    <description>Evaluation of nutritional status by assessing the serum levels of vitamin B9 (ng/mL) and vitamin D (ng/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status evaluation - vitamins</measure>
    <time_frame>Baseline (T0) and after 12 weeks of intervention (T1).</time_frame>
    <description>Evaluation of nutritional status by assessing the serum levels of vitamin B12 (pg/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional status evaluation - hyperhomocysteinemia</measure>
    <time_frame>Baseline (T0) and after 12 weeks of intervention (T1).</time_frame>
    <description>Evaluation of nutritional status by assessing the serum levels of Homocysteine (μM).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric parameters evaluation - weight</measure>
    <time_frame>Baseline (T0).</time_frame>
    <description>Evaluation at baseline of weight (Kg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric parameters evaluation - height and waist circumference</measure>
    <time_frame>Baseline (T0).</time_frame>
    <description>Evaluation at baseline of height (cm) and waist circumference (cm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ponderal status evaluation</measure>
    <time_frame>Baseline (T0).</time_frame>
    <description>Evaluation at baseline of Body Mass Index (Kg/m2) to investigate the prevalence of overweight or obesity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat distribution evaluation.</measure>
    <time_frame>Baseline (T0).</time_frame>
    <description>Evaluation at baseline of Waist to height ratio (WHtR) as a proxy of fat distribution and metabolic diseases risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition evaluation.</measure>
    <time_frame>Baseline (T0).</time_frame>
    <description>Evaluation at baseline of reactance (Ohm) and resistance (Ohm) by using vectorial bioimpedance analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength evaluation.</measure>
    <time_frame>Baseline (T0).</time_frame>
    <description>Evaluation at baseline of muscle strength (Kg) by using a handgrip-dynamometer.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Inflammation</condition>
  <condition>Malnutrition</condition>
  <condition>Hyperglycemia</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Active group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Snack enriched with camelina sativa oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Snack no enriched with camelina sativa oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Novel food snack</intervention_name>
    <description>Consumption of snack enriched with camelina sativa oil, twice a day for 12 weeks</description>
    <arm_group_label>Active group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo snack</intervention_name>
    <description>Consumption of placebo snack (no enriched with camelina sativa oil), twice a day for 12 weeks</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age over 65&#xD;
&#xD;
          -  Free-living&#xD;
&#xD;
          -  No food allergy&#xD;
&#xD;
          -  Apparent good health&#xD;
&#xD;
          -  Acceptance and sign of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 65&#xD;
&#xD;
          -  Living in a nursing home, extended care&#xD;
&#xD;
          -  Hospitalized&#xD;
&#xD;
          -  Presence food allergy&#xD;
&#xD;
          -  Without acceptance and sign of informed consent&#xD;
&#xD;
          -  Taking vitamin supplements/integration and/or omega 3 polyunsaturated fatty acids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hellas Cena, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pavia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pavia</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.food-net.it</url>
    <description>Project website</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammaging</keyword>
  <keyword>Healthy aging</keyword>
  <keyword>Older Adults</keyword>
  <keyword>Omega-3 fatty acid</keyword>
  <keyword>Camelina Sativa</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Micronutrients deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

